Bartosz Małkiewicz

Country flagPoland

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Background. Lymphovascular invasion (LVI) is a vital but often overlooked prognostic factor in prostate cancer. As debates on lymphadenectomy’s overtreatment emerge, understanding LVI laterality gains importance. This study pioneers the investigation into PCa, aiming to uncover patterns that could influence tailored surgical strategies in the future. Methods. Data from 96 patients with both LVI and lymph node invasion (LNI) were retrospectively analyzed. All participants underwent radical prostatectomy (RP) with modified-extended pelvic lymph node dissection (mePLND). All specimens underwent histopathological examination. The assessment of LVI was conducted separately for the right and left lobes of the prostate. Associations within subgroups were assessed using U-Mann–Whitney and Kruskal–Wallis tests, as well as Kendall’s tau-b coefficient, yielding p-values and odds ratios (ORs). Results. Out of the 96 patients, 61 (63.5%) exhibited exclusive left-sided lymphovascular invasion (LVI), 24 (25.0%) had exclusive right-sided LVI, and 11 (11.5%) showed bilateral LVI. Regarding nodal involvement, 23 patients (24.0%) had LNI solely on the left, 25 (26.0%) exclusively on the right, and 48 (50.0%) on both sides. A significant correlation was observed between lateralized LVI and lateralized LNI (p < 0.001), particularly in patients with right-sided LVI only. LN-positive patients with left-sided LVI tended to have higher pT stages (p = 0.047) and increased odds ratios (OR) of bilateral LNI (OR = 2.795; 95% confidence interval [CI]: 1.231–6.348) compared to those with exclusive right-sided LVI (OR = 0.692; 95% CI: 0.525–0.913). Conclusions. Unilateral LVI correlates with ipsilateral LNI in PCa patients with positive LNs, notably in cases of exclusively right-sided LVI. Left-sided LVI associates with higher pT stages and a higher percentage of bilateral LNI cases.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (17)

Wojciech Krajewski

Wroclaw Medical University

POLAND
View details

Tomasz Szydełko

Wroclaw Medical University

POLAND
View details

Artur Lemiński

Pomeranian Medical University

POLAND
View details

Marcin Słojewski

Head of Dept. Prof. of Urology

Pomeranian Medical University

POLAND
View details

Mateusz Czajkowski

Medical University of Gdansk

POLAND
View details

Anna Tomkiewicz

Ludwik Hirszfeld Institute of Immunology and Experimental Therapy

POLAND
View details

Anna Kotulak-Chrząszcz

Medical University of Gdansk

POLAND
View details

Piotr Wierzbicki

Adjunct/Assistant Professor

Medical University of Gdansk

POLAND
View details

Roman Sosnowski

Professor

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

POLAND
View details

Marek Bolanowski

Prof

Medical University of Silesia

POLAND
View details

Agnieszka Siennicka

Head, Vice-Dean (Faculty of Health Sciences)

Wroclaw Medical University

POLAND
View details

Anna Andrzejczak

Ludwik Hirszfeld Institute of Immunology and Experimental Therapy

POLAND
View details

Zbigniew Kmieć

Medical University of Gdansk

POLAND
View details

Aleksandra Pawlak

Wroclaw University of Environmental and Life Sciences

POLAND
View details

Przemysław Szuba

-

POLAND
View details

Kuba Ptaszkowski

Wroclaw Medical University

POLAND
View details

AGNIESZKA HAŁOŃ

Professor

Medical University of Silesia

POLAND
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.